Atlas market file · Equity · United States
Cronos Group Inc.CRON
- Last close
- 3.07
- Change
- +12.87%
- 96-bar range
- 2.38 – 3.26
- As of
- 6 Aug 2026
Cronos Group Inc. is a medicinal chemicals & botanical products issuer listed as CRON on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
CRON
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+31.20% over the window).
Source rail: Yahoo Finance chart API (CRON). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for CRON. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
CRON public profile
Medicinal chemicals & botanical products issuer. Cronos Group Inc. is connected to current market context, cited company sources and its retained research file.
Cronos Group Inc. trades as CRON on NASDAQ. Cronos Group Inc. (CRON) has a latest verified close of 3.07, up 12.87%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files CRON under USA Stocks for browsing.
What changed for Cronos Group Inc. today
Cronos Group Inc. (CRON) reported $45.2M in revenue for the quarter ending March 31, 2026, with net income of $13.8M, according to its 10-Q filing. However, operating income remained negative at $-1.8M, highlighting a disconnect between top-line growth and operational efficiency. The company cited increased supply from its Cronos GrowCo expansion and strong international demand for its Spinach® brand, which now holds 5.0% market share in flower sales.
Cronos’s financials paint a mixed picture: $821.9M in cash and no short-term investments suggest ample liquidity, but a $2.0M inventory build to $48.7M raises questions about demand synchronization. The company’s SD filing detailed conflict minerals compliance, yet offered no roadmap to profitability. Meanwhile, three insider transactions disclosed in May 2026 Form 4 filings totaled minimal volume, doing little to signal executive confidence.
The June 22, 2026, 8-K filing revealed no material changes to operations or capital structure, despite the company’s cash reserves exceeding liabilities ($48.3M) by over 20x. Research and development expenses remained modest at $1.4M, trailing peers in innovation spend. Cronos’s press release emphasized 'sustainable growth,' but with diluted EPS at $0.04 and shares outstanding ballooning to 381.8M, investors are left wondering what exactly is sustaining.
Technical analysis is constrained by the absence of chart data in the source rail, but the fundamentals suggest a company at a crossroads. Cronos’s ability to convert cash into profitable growth remains unproven, and its reliance on a single brand (Spinach®) for market traction introduces concentration risk. The next filing cycle will test whether the 'borderless strategy' is more than a slogan.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
CRON technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on CRON
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep CRON research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
CRON FAQ
What is Cronos Group Inc. (CRON)?Cronos Group Inc. (CRON) has a latest verified close of 3.07, up 12.87%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
Cronos Group Inc. (CRON) has a latest verified close of 3.07, up 12.87%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for CRON?Cronos Group Inc. (CRON) has a latest verified close of 3.07, up 12.87%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
Cronos Group Inc. (CRON) has a latest verified close of 3.07, up 12.87%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files CRON under USA Stocks for browsing.
How often is the CRON page updated?The CRON public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The CRON public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for CRON?The CRON file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CRON. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The CRON file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CRON. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on CRON?Yes. The workstation can open CRON, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open CRON, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this CRON page investment advice?No. The CRON page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The CRON page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →